Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Alexion Pharmaceuticals, |
RCV000857257 | SCV000999846 | likely pathogenic | Lysosomal acid lipase deficiency | 2019-06-01 | criteria provided, single submitter | research | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV003323742 | SCV004030098 | likely pathogenic | Wolman disease | 2023-07-25 | criteria provided, single submitter | clinical testing | Variant summary: LIPA c.931G>A (p.Gly311Arg) results in a non-conservative amino acid change located in the Alpha/beta hydrolase fold-1 domain (IPR000073) of the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant was absent in 251358 control chromosomes. To our knowledge, no occurrence of c.931G>A in individuals affected with Lysosomal Acid Lipase Deficiency has been reported. At least one publication reports experimental evidence evaluating an impact on protein function, with enzymatic activity of the variant protein being <10% of normal activity (Del Angel_2019). The following publication has been ascertained in the context of this evaluation (PMID: 31180157). One submitter has cited clinical-significance assessments for this variant to ClinVar after 2014 and has classified the variant as likely pathogenic. Based on the evidence outlined above, the variant was classified as likely pathogenic. |